Pharmaceutical Productivity Unstable as R&D Costs Escalate
A new study has found that leading research-based pharmaceutical firms have seen the average quantity of compounds in their late-stage development pipelines drop by 22% this year, while R&D costs have increased by over 25%. According to the 2011 yearly review of pharmaceutical R&D value, Measuring the Return from Innovation, by Deloitte and Thomson Reuters,